News | May 20, 2026
Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Subscribe To Our Newsletter & Stay Updated
